0
     

Report Added
Report already added
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 33 molecules. Out of which approximately 33 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 2, 1, 1, 8, 5 and 1 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Metastatic Colorectal Cancer, Non-Proliferative Diabetic Retinopathy (NPDR), Retinal Vein Occlusion, Retinopathy, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Colorectal Cancer, Corneal Neovascularization, Graves' Ophthalmopathy, Macular Degeneration, Medulloblastoma, Optic Neuropathy, Retinoblastoma, Retinopathy Of Prematurity, Solid Tumor, Unspecified Cancer, Unspecified Ophthalmological Disorders and Uveal Melanoma.

The latest report Placenta Growth Factor - Drugs In Development, 2022, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
- The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
Alteogen Inc
Alvotech SA
Amgen Inc
Celltrion Inc
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cinnagen Co
Formycon AG
GlycoNex Inc
Hexal AG
Huons Global Co Ltd
i2 Pharmaceuticals Inc
Johnson & Johnson
Kidswell Bio Corp
Luye Pharma Group Ltd
Mabwell Shanghai Bioscience Co Ltd
Neuracle Genetics Inc
Ocular Therapeutix Inc
Oncosimis Biotech Pvt Ltd
Oxurion NV
Panolos Bioscience
PharmAbcine Inc
Prestige BioPharma Ltd
Regeneron Pharmaceuticals Inc
Rophibio Inc
Sam Chun Dang Pharm Co Ltd
Samsung Bioepis Co Ltd
Shilpa Medicare Ltd
Synermore Biologics Co Ltd
Zeen Biotechnology Co Ltd
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
aflibercept SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
conbercept - Drug Profile
Product Description
Mechanism Of Action
History of Events
KH-906 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NG-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PB-101 - Drug Profile
Product Description
Mechanism Of Action
SL-186 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SL-188 - Drug Profile
Product Description
Mechanism Of Action
History of Events
THR-317 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
History of Events
ziv-aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
Featured News & Press Releases
Jul 14, 2022: New antibody therapy shows promising results for advanced, treatment-refractory pediatric brain cancer
Jul 07, 2022: Alvotech initiates patient study for AVT06, a proposed biosimilar for Eylea
Jun 29, 2022: EYLEA (aflibercept) injection sBLA for Every 16-week dosing regimen in patients with diabetic retinopathy accepted for FDA review
Apr 25, 2022: Shilpa Medicare receives NoC from RCGM, Dept. of Biotechnology for its Biosimilar Aflibercept
Feb 22, 2022: Bayer Gets Eylea Biosame approval in Japan as it braces for biosimilar debuts
Feb 11, 2022: Regeneron presents encouraging phase 2 results for high-dose aflibercept 8 mg in wet age-related macular degeneration at Angiogenesis Meeting
Nov 10, 2021: Bayer submits Aflibercept for regulatory approval in the EU and Japan for retinopathy of prematurity in premature babies
Aug 25, 2021: Regeneron’s aflibercept meets primary goal in Phase II wet AMD trial
Jul 27, 2021: Humana Sues Regeneron Over Price Of Eylea Macular Degeneration Drug
May 04, 2021: Sandoz to study biosimilar aflibercept in Phase III AMD trial
Apr 12, 2021: Oncurious reports encouraging data from phase 1 dose escalation study of TB-403 in paediatric subjects with relapsed or refractory medulloblastoma presented at the American Association for Cancer Research 2021 Annual Meeting
Apr 09, 2021: Kanghong Pharmaceutical stops clinical study of ocular drug Conbercept
Apr 09, 2021: ONCURIOUS presenting clinical and preclinical data at upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting
Mar 31, 2021: Regeneron’s Eylea lowers vision-threatening events in diabetes trial
Mar 28, 2021: Kanghong pharmaceutical: khb-1802 clinical trial suspended in France
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW